Cell population for use in treating cancer
The invention pertains to a cell population for use in treating cancer in a patient, comprising CD1c(BDCA-1) + /CD19 − dendritic cells, wherein CD1c(BDCA-1) + /CD19 − dendritic cells are depleted for CD1c(BDCA-1) + /CD19 − /CD14 + cells.
1. A cell population for use in treating cancer in a patient, comprising:
CD1c+/CD19− myeloid dendritic cells, wherein less than or equal to 25% of the CD1c+/CD19− dendritic cells are CD1c+/CD19−/CD14+ cells; and
cells that are CD304+(BDCA-4+) plasmacytoid dendritic cells.
2. The cell population of claim 1 , wherein at least 50% of the cells are loaded with a tumor antigen or a tumor peptide.
3. The cell population of claim 1 , wherein the cells are purified from blood of the patient to be treated for cancer.
4. The cell population of claim 1 , wherein the cancer is a solid cancer or a blood cancer.
5. The cell population of claim 4 , wherein the cancer is chronic myeloid leukemia.
6. The cell population of claim 4 , wherein the cancer is melanoma or prostate cancer.
7. The cell population of claim 1 , wherein when the cell population includes less than or equal to 25% of the CD1c+/CD19− dendritic cells being CD1c+/CD19−/CD14+ cells the cell population has a reduced immunosuppressive activity compared to a cell population wherein more than 25% of the CD1c+/CD19− dendritic cells are CD1c+/CD19−/CD14+ cells.